Fig. 1. Profile of vaccine candidates against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) based on platform and
clinical stage. 63 vaccine candidates are in clinical evaluation, while
179 candidates are still in the preclinical stage. The highest frequency
is related to protein subunit vaccines and none of the vaccines with
LABV and rBV platforms have entered the clinical experiments. nrVV,
non-replicating viral vector; rVV, replicating viral
vector; VLP, virus-like particles;
rBV, replicating bacteria vector; LABV, live attenuated bacterial
vector.
Table 2. The pioneers in the race of putative vaccine
candidates against COVID-19 according to the World Health Organization
reports.